Aselizumab is an immunosuppressive drug which has been investigated for the use in severely injured patients. It binds to CD62L. Seekamp A, van Griensven...
2 KB (80 words) - 01:11, 26 April 2022
Priliximab Teneliximab Vapaliximab Humanized Immunosuppressive: Apolizumab§ Aselizumab Atezolizumab Benralizumab Camrelizumab† Cedelizumab Certolizumab pegol...
38 KB (4,316 words) - 10:24, 26 August 2024
(diagnosis) Ascrinvacumab mab human activin receptor-like kinase 1 cancer Aselizumab mab humanized L-selectin (CD62L) severely injured patients Atezolizumab...
136 KB (4,020 words) - 06:13, 27 September 2024
Asbron Asceniv ascorbic acid (INN) Ascorbicap Ascriptin Asellacrin 10 aselizumab (INN) asenapine (INN) Asendin aseripide (INN) Aservo Equihaler asfotase...
11 KB (530 words) - 20:38, 27 August 2024
Gomiliximab Lumiliximab CD40 Teneliximab Toralizumab CD62L/L-selectin Aselizumab CD80 Galiximab CD147/Basigin Gavilimomab CD154 Frexalimab Ruplizumab BLyS...
7 KB (299 words) - 13:45, 27 April 2024
Priliximab Teneliximab Vapaliximab Humanized Immunosuppressive: Apolizumab§ Aselizumab Atezolizumab Benralizumab Camrelizumab† Cedelizumab Certolizumab pegol...
2 KB (87 words) - 01:28, 30 May 2023
Gomiliximab Lumiliximab CD40 Teneliximab Toralizumab CD62L/L-selectin Aselizumab CD80 Galiximab CD147/Basigin Gavilimomab CD154 Frexalimab Ruplizumab BLyS...
38 KB (2,656 words) - 12:11, 30 October 2023